logo-loader
HealthCannabis
Canntab Therapeutics Ltd

Canntab Therapeutics making final steps towards bringing its products to market

The group said it would start manufacturing commercial batches of oil-filled gel capsules at its facility in Ontario and request Health Canada approval to begin full scale production and sale

Coloured pills
Canntab also said that most of the construction has been completed at the wholly-owned Ontario facility

Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) is eyeing near term revenue from its cannabis oil gel capsules as it continues to work towards bringing the product to market, it told investors Wednesday.

In a corporate update, the group said it would start manufacturing commercial batches of oil-filled gel capsules at its facility in Ontario and request Health Canada approval to begin full scale production and sale.

In Toronto, Canntab shares were just over 3% higher at $0.50 having been 9.3% higher earlier.

READ: Canntab Therapeutics inks pact with Heritage Cannabis for processing hemp for CBD-filled gelcaps

Elsewhere, the Toronto-based company said that most of the construction has been completed at its wholly-owned Ontario facility for the purpose of preparing for a Health Canada inspection. This is the final step before the granting of key 'Licenced Producer' status.

"We are excited to enter this new phase in our development, with manufacturing beginning in the Cobourg facility and construction nearing completion in Markham, we are taking the final steps necessary to bring our products to market," Jeff Renwick, the co-founder and CEO of Canntab Therapeutics said in a statement.

"Oil-filled gel capsules will represent the first stream of revenue for Canntab before we are able to launch our flagship hard tablet products in October, pending Health Canada approval. Our line of solid oral dosage forms with timed release properties is expected to be the future of medical cannabis," he added.

Elsewhere, the firm said cultivation at its hemp farm in Caledon, Ontario was advancing with established plants that have thrived in an excellent growing season.

The group noted that harvesting will begin next week and continue until the end of the season, which is at the beginning of October.

Canntab also revealed it has hired an experienced pharmacist and drug formulation specialist Erin Kofman who will assist with its application to Health Canada for approval of the firm's various dosage forms.

Canntab's product list includes oil-filled gel capsules, an oral quick dissolve tablet and an extended release solid oral formulation.

 -- Adds share price --

Contact the author at [email protected]

Quick facts: Canntab Therapeutics Ltd

Price: $0.60

Market: CSE
Market Cap: $14.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Canntab Therapeutics building cannabis delivery facility with FSD Pharma

Canntab Therapeutics Ltd (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein tell Proactive Investor's Christine Corrado the cannabis delivery manufacturing company is lining up its ducks ahead of the legalization of cannabis in Canada on October 17 this year - as it announced a profit...

on 20/7/18

2 min read